Primary Prevention versus Screening for Prostate Cancer (Prev vs Screen)

The objective of this research is to provide a quantitative framework for researchers and policy makers developing prevention and screening programs to control prostate cancer. This project develops a comprehensive computer microsimulation model of prostate cancer prevention and screening, and uses the model together with data from the Prostate Cancer Prevention Trial to project the incremental costs and benefits of different strategies combining finasteride with PSA screening. This activity is supported by a grant from the National Institute of Health/National Cancer Institute (R01 CA100778).

Publications

Pinsky P, Etzioni R, Howlader, N, Goodman P, Thompson, I. Modeling the Effect of a Preventive Intervention on the Natural History of Prostate Cancer: Application to the Prostate Cancer Prevention Trial. International Journal of Biostatistics. 2006 2(1): Article 12. Available at: http://www.bepress.com/ijb/vol2/iss1/12. Full Text

Etzioni R, Howlander N, Shaw P, Ankerst DK, Penson DF, Goodman P, Thompson IM. Long-term Effects of Finasteride on PSA Levels: Results from the Prostate Cancer Prevention Trail. Journal of Urology. 2005 September; 174(3): 877-81. Abstract / Full Text

Zeliadt SB, Etzioni R, Penson DF, Thompson IM, Ramsey SD. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. American Journal of Medicine. 2005 August; 118(8): 850-7. Abstract / Full Text

Figure legend:
The effect of finasteride on expected lifetime prostate cancer deaths by age for 1000 men beginning treatment at age 55 years (base case). (Zeliadt, Am J Med, 2005)